New, ongoing, free event series about researchers work in the exciting fields of multi-omics. Each session will take a particular field of omics research and showcase some of the exciting research being undertaken from around the world.

Easier access for central European companies to cryo-EM technique! A modern Thermo Scientific Glacios transmission electron microscope has just been installed at Synchrotron Solaris in Poland and it is open for industrial users.

Luxembourg-headquartered Covis is taking two COPD drugs off AstraZeneca’s hands in a US$270m deal.

This white paper focuses on a new generation of single-use bioreactors, built to deliver high-volume performance and how they address many issue.

Eisbach Bio GmbH is a spin-off of the Ludwig Maximilian University in Munich. The company is located in the Innovation and Start-up Centre IZB in Planegg-Martinsried.

Belgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma.

German drug discovery company Evotec plans to raise US$576m on the US-American stock exchange Nasdaq to finance extensive investments.

Institut Curie spin-off Egle Therapeutics has raised €40m in a Series A financing. The company will use the funds to develop First-In-Class T-regulatory cells therapies based on Treg starvers.

The French company has taken big steps to scale up its process for converting plant-based feedstocks into isobutene, bringing affordable aviation biofuels into reach.

Gene Editing?CRISPR-Cas9 gene editing offers substantial improvements over previous gene editing technologies in terms of ease of use, speed, efficacy, and cost. Not surprisingly, CRISPR-Cas9 editing has taken biomedical science by storm. While the technology is relatively simple in handling at the level of basic research, the use of CRISPR genome editing in therapeutical applications poses a bunch of
analytical challenges.